308 related articles for article (PubMed ID: 30419950)
1. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Qiu J; You L; Zheng L; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2018 Nov; 37(1):274. PubMed ID: 30419950
[TBL] [Abstract][Full Text] [Related]
2. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Cui J; Guo Y; Wu H; Xiong J; Peng T
Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
[TBL] [Abstract][Full Text] [Related]
5. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
6. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
7. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
9. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells.
Zhu J; Chen Y; Ji Y; Yu Y; Jin Y; Zhang X; Zhou J
Biotechnol Appl Biochem; 2018 Sep; 65(5):665-671. PubMed ID: 29575133
[TBL] [Abstract][Full Text] [Related]
11. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
[TBL] [Abstract][Full Text] [Related]
12. Choroid plexus LAT2 and SNAT3 as partners in CSF amino acid homeostasis maintenance.
Dolgodilina E; Camargo SM; Roth E; Herzog B; Nunes V; Palacín M; Verrey F
Fluids Barriers CNS; 2020 Feb; 17(1):17. PubMed ID: 32046769
[TBL] [Abstract][Full Text] [Related]
13. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
[TBL] [Abstract][Full Text] [Related]
14. Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
Mukhopadhyay S; Goswami D; Adiseshaiah PP; Burgan W; Yi M; Guerin TM; Kozlov SV; Nissley DV; McCormick F
Cancer Res; 2020 Apr; 80(8):1630-1643. PubMed ID: 31911550
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
16. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
17. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
[TBL] [Abstract][Full Text] [Related]
18. Recycling of aromatic amino acids via TAT1 allows efflux of neutral amino acids via LAT2-4F2hc exchanger.
Ramadan T; Camargo SM; Herzog B; Bordin M; Pos KM; Verrey F
Pflugers Arch; 2007 Jun; 454(3):507-16. PubMed ID: 17273864
[TBL] [Abstract][Full Text] [Related]
19. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.
Chen R; Lai LA; Sullivan Y; Wong M; Wang L; Riddell J; Jung L; Pillarisetty VG; Brentnall TA; Pan S
Sci Rep; 2017 Aug; 7(1):7950. PubMed ID: 28801576
[TBL] [Abstract][Full Text] [Related]
20. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells.
Kagawa S; Takano S; Yoshitomi H; Kimura F; Satoh M; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Furukawa K; Matsushita K; Nomura F; Miyazaki M
J Surg Res; 2012 Dec; 178(2):758-67. PubMed ID: 22726648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]